Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

Conditions: Thyroid Neoplasms Interventions: Combination Product: Iodine-125 brachytherapy combine with Anlotinib Sponsors: Jiangxi Provincial Cancer Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials